TC
LAB icon

TFS Capital’s Standard BioTools LAB Stock Holding History

TFS Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-17,211
Closed -$758K – 1243
2014
Q1 		$758K Sell
17,211
-12,076
-41% -$531K 0.05% 563
2013
Q4 		$1.12M Sell
29,287
-41,392
-59% -$1.22M 0.05% 512
2013
Q3 		$1.55M Buy
+70,679
New +$1.39M 0.07% 419

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TFS Capital's LAB Position: Q2 2014 in Review

TFS Capital sold out of Standard BioTools (LAB) in Q2 2014, closing a stake of 17,211 shares — an estimated $758K sold.

TFS Capital first reported a position in LAB in Q3 2013 and held it in 3 quarters. The position peaked at $1.55M in Q3 2013. 104 funds tracked by Wall St. Rank hold LAB as of Q2 2014.

  • TFS Capital reported no remaining Standard BioTools position as of Q2 2014 after selling out during the quarter.
  • TFS Capital sold 17,211 Standard BioTools shares in Q2 2014, an estimated $758K.
  • TFS Capital first reported a position in Standard BioTools in Q3 2013 and held it in 3 quarters.
  • TFS Capital's Standard BioTools position peaked at $1.55M in Q3 2013.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2014.

Based on TFS Capital's 13F filing for Q2 2014, filed 21 Jul 2014.